Clinical trial

Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC

NCT03884192

Study summary

ClinicalTrials.gov

Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Consolidation Sintilimab Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2018-12-12

PhasePHASE3

Conditions

Carcinoma, Non-Small Cell Lungunresolved

Interventions

Consolidation SintilimabDRUG

Sponsors & collaborators

Shandong Cancer Hospital and Institutelead sponsor

Mapped research locations

JinanShandong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03884192 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.